Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A multi-center, randomized, open, non-inferiority, Phase 4 study
A Multi-center, Randomized, Interventional, Open, Phase Ⅳ Clinical Trial on Education Method of Fluterol® Inhalation Capsule 250/50 μg Inhaler for Asthma Control in Patients with Partly Controlled Asthma
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental group (one-way education) | Experimental | Experimental group (one-way education)
|
|
| Control group(two-way education) | Active Comparator | Control group(two-way education)
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| one-way education | Drug | 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education' |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent change in Forced expiratory volume 1 sec (% prediction) at Week 12 from baseline in each group. | method of assessment:Forced expiratory volume | Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| percent change in Forced expiratory volume 1 sec (% prediction) at Week 4 from baseline in each group. | method of assessment:Forced expiratory volume | Week 4 |
| Change in asthma control (ACT) at Weeks 4 and 12 from baseline in each group. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
History of hypersensitivity reactions to the investigational product (Fluterol®) or any of its component.
Cardiac tachyarrhythmia.
contreated respiratory fungal, bacterial, or tuberculous infection.
Moderate to severe bronchiectasis
Planned use of the investigational product (Fluterol®) as primary treatment for patients with status asthmaticus, patients with an asthmatic crisis*, or patients with chronic obstructive pulmonary disease requiring intensive treatment.
Administration of systemic steroids within 2 weeks prior to screening.
Hypersensitivity reactions to lactose and milk.
Pregnant and lactating women or women who are planning to be pregnant or who are unwilling to use appropriate methods of contraception during the study.
Previous use of the investigational product (Fluterol®) or a similar inhaler (Onbrez, Spiriva) at least once.
Participation in another clinical study for drugs or medical devices to receive the investigational product or undergo a procedure using the investigational device within 4 weeks prior to participation in this study.
Individual considered by the he investigator to be inappropriate for study participation due to other reasons.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Byoung Whui Choi | Chung-Ang University Hospital | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| two-way education | Drug | 'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education' |
|
|
method of assessment: Check list
| Weeks 4 and 12 |
| Change in inhaler technique score at Weeks 4 and 12 from baseline in each group | method of assessment: Check list | Weeks 4 and 12 |
| Number of critical errors at Weeks 4 and 12 in each group. | method of assessment: Check list | Weeks 4 and 12 |
| Proportion of subjects with optimal inhaler technique at Weeks 4 and 12 in each group. | method of assessment: Check list | Weeks 4 and 12 |
| Satisfaction for the inhalation drug at Weeks 4 and 12 in each group (FSI-10 score). | method of assessment: Check list | Weeks 4 and 12 |
| Adherence rate (%) at Weeks 4 and 12 in each group. | method of assessment: drug administration calculation | Weeks 4 and 12 |
| Safety endpoint:AEs(adverse events), vital signs, incidence rate of acute exacerbation. | occur frequency of adverse events and incidence rate of acute in each group, vital signs: blood pressure and pulse | baseline(day1),weeks 4 and weeks12 |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |